A CD79b targeting ADC with superior anti-tumor activity and therapeutic index

被引：0
|
作者：
Attinger-Toller, Isabella [1 ]
Probst, Philipp [1 ]
Bertrand, Romain [1 ]
Stark, Ramona [1 ]
Santimaria, Roger [1 ]
Renard, Emma [1 ]
Fay, Rachael [1 ]
Grabulovski, Dragan [1 ]
Schlereth, Bernd [1 ]
Spycher, Philipp Rene [1 ]
机构：
[1] Araris Biotech AG, Zurich, Switzerland
来源：
CANCER RESEARCH | 2022年 / 82卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2910
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A CD79b Targeting ADC with Superior Anti-Tumor Activity and Safety Resulting in Significantly Improved Therapeutic Index (TI): Safe and Efficacious CD79b ADC
    Schlereth, Bernd
    Attinger-toller, Isabella
    Probst, Philipp
    Bertrand, Romain
    Stark, Ramona
    Santimaria, Roger
    Renard, Emma
    Fay, Rachael
    Sharman, Jeff P.
    Grabulovski, Dragan
    Spycher, Philipp
    BLOOD, 2022, 140 : 11568 - 11569
  • [2] CD79b targeting ADC with superior pharmacokinetic profile and anti-tumor activity.
    Spycher, Philipp Rene
    Probst, Philipp
    Bertrand, Romain
    Stark, Ramona
    Santimaria, Roger
    Grabulovski, Dragan
    Attinger-Toller, Isabella
    CANCER RESEARCH, 2021, 81 (13)
  • [3] Therapeutic targeting of the BCR-associated protein CD79b in a TCR-based approach is hampered by aberrant expression of CD79b
    Jahn, Lorenz
    Hombrink, Pleun
    Hassan, Chopie
    Kester, Michel G. D.
    van der Steen, Dirk M.
    Hagedoorn, Renate S.
    Falkenburg, J. H. Frederik
    van Veelen, Peter A.
    Heemskerk, Mirjam H. M.
    BLOOD, 2015, 125 (06) : 949 - 958
  • [4] A Phase I Study of the Anti-CD79b Antibody-Drug Conjugate (ADC) DCDS4501A Targeting CD79b in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
    Palanca-Wessels, Maria Corinna
    Flinn, Ian W.
    Sehn, Laurie H.
    Patel, Manish
    Sangha, Randeep
    Czuczman, Myron S.
    Salles, Gilles Andre
    Morschhauser, Franck
    Advani, Ranjana
    Press, Oliver W.
    Ho, William
    Kahn, Robert
    Lu, Dan
    Su, Zheng
    Chu, Yu-Waye
    Assouline, Sarit E.
    BLOOD, 2012, 120 (21)
  • [5] In vivo effects of targeting CD79b with antibodies and antibody-drug conjugates
    Zheng, Bing
    Fuji, Reina N.
    Elkins, Kristi
    Yu, Shang-Fan
    Fuh, Franklin K.
    Chuh, Josefa
    Tan, Christine
    Hongo, Jo-Anne
    Raab, Helga
    Kozak, Katherine R.
    Williams, Marna
    McDorman, Elena
    Eaton, Dan
    Ebens, Allen
    Polson, Andrew G.
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (10) : 2937 - 2946
  • [6] Inhibition of anti-tumor immunity by NF-κB: Toward therapeutic targeting?
    Revol-Bauz, Lara
    Grinberg-Bleyer, Yenkel
    M S-MEDECINE SCIENCES, 2022, 38 (02): : 230 - 232
  • [7] HMA800067, a novel CD38-targeting antibody-drug conjugate (ADC), demonstrated superior anti-tumor activity to daratumumab in preclinical B-cell malignancies models
    Xu, Yan
    Liang, Junqing
    Jiang, Shuwen
    Yang, Haibin
    Zhang, Hui
    Mao, Fangfang
    Zhu, Jiahuan
    He, Jianlin
    Yang, Na
    Wang, Jian
    Zhang, WeiHan
    Ren, Yongxin
    Su, Weiguo
    CANCER RESEARCH, 2024, 84 (06)
  • [8] Regulation of B cell activity by inducing specific autoimmune response against CD79b
    Chen, LYY
    Sheu, JJC
    Chang, TW
    FASEB JOURNAL, 2000, 14 (06): : A1123 - A1123
  • [9] CD49b Targeting Inhibits Tumor Growth and Boosts Anti-tumor Immunity
    Contreras-Kallens, Pamina
    Galvez-Jiron, Felipe
    De Solminihac, Javiera
    Elhusseiny, Ahmed
    Gonzalez-Arriagada, Wilfredo A.
    Alcayaga-Miranda, Francisca
    Noelle, Randolph J.
    Pino-Lagos, Karina
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [10] Superior anti-tumor activity of NC18, a novel HER2-targeting ADC, against enhertu-resistant CDX model
    Zhi, L.
    Sun, B.
    Kan, X.
    Ren, S.
    ANNALS OF ONCOLOGY, 2024, 35 : S1477 - S1477
12345